Form 144 - Report of proposed sale of securities:
SEC Accession No. 0000947871-25-000375
Filing Date
2025-04-09
Accepted
2025-04-09 18:51:50
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 144  
1 primary_doc.xml 144 3071
  Complete submission text file 0000947871-25-000375.txt   4811
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED CAPITAL LLC (Reporting) CIK: 0001157524 (see all company filings)

EIN.: 134133323 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 144

Mailing Address 80 GUEST STREET BOSTON MA 02135
Business Address 80 GUEST STREET BOSTON MA 02135 617-500-8099
Compass Therapeutics, Inc. (Subject) CIK: 0001738021 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 144 | Act: 33 | File No.: 001-39696 | Film No.: 25826171
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)